DE2127172A1 - Arzneimittel zur Behandlung virus bedingter Infektionen - Google Patents
Arzneimittel zur Behandlung virus bedingter InfektionenInfo
- Publication number
- DE2127172A1 DE2127172A1 DE19712127172 DE2127172A DE2127172A1 DE 2127172 A1 DE2127172 A1 DE 2127172A1 DE 19712127172 DE19712127172 DE 19712127172 DE 2127172 A DE2127172 A DE 2127172A DE 2127172 A1 DE2127172 A1 DE 2127172A1
- Authority
- DE
- Germany
- Prior art keywords
- viruses
- virus
- infections caused
- max
- treat infections
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000700605 Viruses Species 0.000 title claims description 20
- 239000003814 drug Substances 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 title claims description 4
- 208000015181 infectious disease Diseases 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000700618 Vaccinia virus Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000004452 microanalysis Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000002211 ultraviolet spectrum Methods 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 239000008366 buffered solution Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229940109171 rifamycin sv Drugs 0.000 description 4
- 238000001429 visible spectrum Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BBNQHOMJRFAQBN-UPZFVJMDSA-N 3-formylrifamycin sv Chemical class OC1=C(C(O)=C2C)C3=C(O)C(C=O)=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BBNQHOMJRFAQBN-UPZFVJMDSA-N 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 239000001913 cellulose Chemical class 0.000 description 3
- 229920002678 cellulose Chemical class 0.000 description 3
- -1 polyoxyethylene Polymers 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 239000004296 sodium metabisulphite Substances 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 201000005332 contagious pustular dermatitis Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- IYPZRUYMFDWKSS-UHFFFAOYSA-N piperazin-1-amine Chemical class NN1CCNCC1 IYPZRUYMFDWKSS-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Fodder In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT25381/70A IT1046627B (it) | 1970-06-01 | 1970-06-01 | Composizioni antivirali contenenti derivati della rifaumicina sv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2127172A1 true DE2127172A1 (de) | 1971-12-16 |
Family
ID=11216534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712127172 Pending DE2127172A1 (de) | 1970-06-01 | 1971-06-01 | Arzneimittel zur Behandlung virus bedingter Infektionen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US3796798A (enExample) |
| JP (1) | JPS4921764B1 (enExample) |
| BE (1) | BE767845A (enExample) |
| DE (1) | DE2127172A1 (enExample) |
| FR (1) | FR2100710B1 (enExample) |
| GB (1) | GB1319868A (enExample) |
| IL (1) | IL36617A (enExample) |
| IT (1) | IT1046627B (enExample) |
| NL (1) | NL7105341A (enExample) |
| ZA (1) | ZA712420B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2728869A1 (de) * | 1976-06-25 | 1977-12-29 | Antibiotice Iasi Intreprindere | Rifamycinen und verfahren zu deren herstellung |
| DE2846321A1 (de) * | 1977-11-25 | 1979-05-31 | Holco Investment Inc | Verfahren zur herstellung von rifamycinen |
| EP0284552A1 (de) * | 1987-03-06 | 1988-09-28 | Ciba-Geigy Ag | 4-Benzyl-piperazinyl-Hydrazone |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3574142D1 (en) * | 1985-10-18 | 1989-12-14 | Ciba Geigy Ag | Substituted 4-benzyl-piperazinyl compounds |
| WO1989002894A1 (fr) * | 1987-09-25 | 1989-04-06 | Ciba-Geigy Ag | Derives diacyle de la 4-(trialkylbenzyle)-piperazinyle |
| US6143740A (en) * | 1996-11-19 | 2000-11-07 | Georgetown University | Heregulin antagonists and methods for their use |
| US20090275594A1 (en) * | 2008-05-05 | 2009-11-05 | Macielag Mark J | 3-hydrazone piperazinyl rifamycin derivatives useful as antimicrobial agents |
-
1970
- 1970-06-01 IT IT25381/70A patent/IT1046627B/it active
-
1971
- 1971-04-14 IL IL36617A patent/IL36617A/xx unknown
- 1971-04-15 ZA ZA712420A patent/ZA712420B/xx unknown
- 1971-04-20 NL NL7105341A patent/NL7105341A/xx unknown
- 1971-05-17 JP JP46033202A patent/JPS4921764B1/ja active Pending
- 1971-05-28 BE BE767845A patent/BE767845A/xx unknown
- 1971-05-28 FR FR7119539A patent/FR2100710B1/fr not_active Expired
- 1971-05-28 GB GB1798871A patent/GB1319868A/en not_active Expired
- 1971-06-01 DE DE19712127172 patent/DE2127172A1/de active Pending
- 1971-06-01 US US00149086A patent/US3796798A/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2728869A1 (de) * | 1976-06-25 | 1977-12-29 | Antibiotice Iasi Intreprindere | Rifamycinen und verfahren zu deren herstellung |
| DE2846321A1 (de) * | 1977-11-25 | 1979-05-31 | Holco Investment Inc | Verfahren zur herstellung von rifamycinen |
| EP0284552A1 (de) * | 1987-03-06 | 1988-09-28 | Ciba-Geigy Ag | 4-Benzyl-piperazinyl-Hydrazone |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1046627B (it) | 1980-07-31 |
| FR2100710A1 (enExample) | 1972-03-24 |
| FR2100710B1 (enExample) | 1975-06-06 |
| ZA712420B (en) | 1972-01-26 |
| IL36617A (en) | 1975-03-13 |
| IL36617A0 (en) | 1971-06-23 |
| NL7105341A (enExample) | 1971-12-03 |
| US3796798A (en) | 1974-03-12 |
| BE767845A (fr) | 1971-10-18 |
| JPS4921764B1 (enExample) | 1974-06-04 |
| GB1319868A (en) | 1973-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2527065A1 (de) | 5-propylthio-2-benzimidazolcarbaminsaeuremethylester | |
| DE2127172A1 (de) | Arzneimittel zur Behandlung virus bedingter Infektionen | |
| DE1949813C3 (de) | 3-<4-Pvridyl)-4-(2-hydroxvphenyl)-5-alkyl-pyrazole | |
| DE2101378A1 (de) | Neue pharmazeutische Zusammensetzungen zur Behandlung von Bakterieninfektionen | |
| DE1811518B2 (de) | Daunorubicinderivale, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
| DE2007345A1 (de) | Neue substituierte Hexahydroimidazochinoline und deren Säureanlagerungssalze | |
| EP0098577A2 (de) | Arzneimittel zur Behandlung von infektiös bedingten Diarrhöen | |
| DE69627355T2 (de) | Durch strahlung aktivierte cytotoxin therapie | |
| DE2236876C3 (de) | N-Substituierte Aminocarbonsäuren und diese Verbindungen enthaltende Arzneimittel | |
| DE60318561T2 (de) | Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie | |
| DE3116250C2 (enExample) | ||
| DE2347220C3 (de) | L-Cystin-bis-[2,2-bis-(2-chloräthyl)-hydrazid] -dihydrobromid, Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel | |
| DE69829905T2 (de) | Heilmittel für durch Helicobacter verursachte Krankheit | |
| DE2825445A1 (de) | Rifamycin-verbindungen | |
| DE2436959C2 (de) | Antibakterielle zusammensetzung mit einem gehalt an einer verbindung vom 3-fluor-d-alanin-typ und einer n-substituierten cycloserinverbindung | |
| DE2351860A1 (de) | Arzneimittel, enthaltend salze von sulfoglykopeptiden mit natuerlichen oder synthetischen stickstoffhaltigen organischen verbindungen | |
| DE3706399A1 (de) | Mittel mit antidepressiver wirkung | |
| DE2063173C3 (de) | 3- (5- Bromph enyl-2-tetr az olyl) propionylamide, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
| DE2659104C2 (enExample) | ||
| DE2127171A1 (de) | Arzneimittel zur Behandlung von Viruserkrankungen | |
| DE1147589B (de) | Verfahren zur Herstellung von bakterizid wirksamen, in 3-Stellung substituierten Derivaten des 1-(5-Nitrofurfuryliden-amino)-hydantoins | |
| DE1695998C3 (de) | N hoch 2, N hoch 3-Di-spiro-tripiperazlnium-salze und Verfahren zu ihrer Herstellung | |
| DE2818498C2 (enExample) | ||
| AT362504B (de) | Verfahren zur herstellung von neuen clavulan- saeureaethern | |
| EP0350742A1 (de) | 6-Merkaptopurin-Derivate, ihre Herstellung und ihre Verwendung zur Bekämpfung von Retrovirusinfektionen |